Search Within

Urvi A Shah

  1. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (67)
  2. Journal Article (18)
  3. Research Letter (5)
  4. Correspondence (3)
Groups
  1. CTCR Scholars (93)
  2. Department of Medicine (93)
  3. Epidemiology and Biostatistics (93)
  4. Hematologic Malignancies, Division of (93)
  5. Biostatistics Service (92)
  6. Center for Hematologic Malignancies (91)

More Groups

People
  1. Alexander Lesokhin (88)
  2. Malin Hultcrantz (85)
  3. Sham Mailankody (84)
  4. Hani Hassoun (83)
  5. Neha Korde (81)
  6. Carlyn Rose Tan (77)

More People

Years
  1. 2025 (3)
  2. 2024 (18)
  3. 2023 (25)
  4. 2022 (23)
  5. 2021 (11)
  6. 2020 (10)

More Years

Publications
  1. Blood (35)
  2. Clinical Lymphoma, Myeloma and Leukemia (23)
  3. Journal of Clinical Oncology (10)
  4. Blood Cancer Journal (6)
  5. American Journal of Hematology (2)
  6. Blood Advances (2)

More Publications

Publishers
  1. American Society of Hematology (37)
  2. Elsevier Inc. (25)
  3. American Society of Clinical Oncology (10)
  4. Nature Publishing Group (8)
  5. American Association for Cancer Research (3)
  6. Ferrata Storti Foundation (2)

More Publishers

Results (93)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: A retrospective study of 34 patients highlighting the need for consensus criteria
    Meeting Abstract

    Pianko, M. J.; Tiutan, T.; Derkach, A.; Jaffer-Sathick, I.; Rossi, A.; Salvatore, S.; Landau, H.; Lahoud, O.; Korde, N.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Microbial changes in response to a plant-based diet and/or supplements in SMM patients: A national multi-arm randomized prospective telehealth study via HealthTree: The nutrition prevention (NUTRIVENTION-2) study
    Meeting Abstract

    Castro, F.; Sweeney, N. W.; Derkach, A.; Traore, K.; Anuraj, A.; Guttentag, L.; Blaslov, J.; Sahagun, A.; Hydren, J.; Chmielewski, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real-world single center experience
    Meeting Abstract

    Hultcrantz, M.; Derkach, A.; Hassoun, H.; Korde, N.; Maclachlan, K. H.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C.; Akhlaghi, T.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A randomized placebo controlled study of a plant-based dietary versus supplement versus placebo intervention in patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) - the Nutrition Prevention (NUTRIVENTION-3) study
    Meeting Abstract

    Shah, U. A.; Castro, F.; Anuraj, A.; Schach, E.; Derkach, A.; Joseph, N. S.; Adintori, P. A.; Guttentag, L.; Blaslov, J.; Cross, J. R.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A pilot plant based dietary intervention in MGUS and SMM patients with elevated BMI is feasible and associated with improvements in metabolic and microbiome biomarkers of progression
    Meeting Abstract

    Shah, U. A.; Derkach, A.; Castro, F.; Anuraj, A.; Blaslov, J.; Tran, L.; Adintori, P. A.; Burge, M.; Funkhouser, S.; Hosszu, K.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 2 trial of colesevelam for lenalidomide-associated diarrhea
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Korde, N.; Mailankody, S.; Shekarkhand, T.; Burge, M.; Maclachlan, K. H.; Patel, D.; Shah, U. A.; Chung, D. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Maintenance Therapy Cessation for Sustained MRD Negative Multiple Myeloma Patients
    Meeting Abstract

    Korde, N.; Diamond, B.; Burge, M.; Hassoun, H.; Landau, H.; Hultcrantz, M.; Mailankody, S.; Maclachlan, K. H.; Shah, U. A.; Derkach, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Carfilzomib, lenalidomide and dexamethasone (KRd) vs bortezomib, lenalidomide, and dexamethasone (VRd) as induction therapy in newly diagnosed high-risk multiple myeloma
    Meeting Abstract

    Tan, C.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Patel, D.; Maclachlan, K. H.; Lahoud, O. B.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Stem cell autograft minimal residual disease negativity improves outcomes after autotransplant for multiple myeloma
    Meeting Abstract

    Nishimura, N.; Brown, S.; Devlin, S. M.; Dahi, P. B.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Hassoun, H.; Hultcrantz, M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
    Correspondence

    Nath, K.; Shekarkhand, T.; Salcedo, M.; Derkach, A.; Rueda, S.; Chansakul, A.; Hulcrantz, M.; Korde, N.; Shah, U. A.; Tan, C.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save